The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Poly(lactic-co-glycolic acid)/polyethylenimine (PLGA/PEI) particles and methods directed to the preparation of PLGA/PEI particles are provided. Methods of using PLGA/PEI particles for the proliferation of stem cells and/or delivery of stem cells are also provided. For example, methods of treating a subject having, or at risk of developing, a cardiovascular disorder can include administering a therapeutically effective amount of stem cell-loaded PLGA/PEI particles to the subject.

The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

The present invention relates in part to a multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the multiparticulate sprinkle dosage forms.

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

A cartridge for delivery of a material therefrom which has a corrugated portion to allow for bending/extending to be applied to the device from which a material to be deposited can be dispensed. The bendability and extendibility allow for greater efficiency in use and application of the material into cavities, pockets, and/or crevices where one needs to deposit the material.

A cartridge for delivery of a material therefrom which has a corrugated portion to allow for bending/extending to be applied to the device from which a material to be deposited can be dispensed. The bendability and extendibility allow for greater efficiency in use and application of the material into cavities, pockets, and/or crevices where one needs to deposit the material.

In some aspects, the present disclosure pertains to methods of treating a tissue volume comprising (a) administering an implantable composition comprising a releasable membrane-active agent to a target site such that the membrane-active agent is locally released to the tissue volume and (b) performing irreversible, reversible and/or thermal treatment by application of a pulsed electric field to the tissue volume. In other aspects, the present disclosure pertains to embolic compositions that comprise releasable membrane-active agents.

The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.